Extended Data Table 4 Summary of objective response assessed by investigator (ITT population with measurable disease at baseline)

From: First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study

  1. (1) Best overall response is defined as the best response during the period between the first dose and the first documented PD, death, or any new anti-cancer therapy, whichever occurs first.
  2. Patients are classified as not applicable if no post baseline response assessments available.
  3. (2) 95% CI for objective response rate is calculated using Clopper-Pearson method.
  4. (3) P-value is calculated using the stratified by stratification factors (PD-L1, ECOG Performance Status and Distant Metastatic from IWRS) Cochran-Mantel-Haenszel Chi-Square test. 95% CI for difference in objective response rates is estimate using normal approximation of binomial distributions. The P value is two-sided.
  5. CI: Confidence Interval.
Back to article page